Back Pain Cell Therapy Trial Completes Patient Enrollment, Paving Way for 2027 Data Readout
Published on 08/17/2026 at 15:05 | Redaktion boerse-global.de
A regenerative medicine candidate targeting one of the world's most common causes of disability has finished treating patients in its pivotal late-stage trial, its developer announced on 17 August 2026.
Mesoblast said all 350 participants in the Phase 3 study MSB-DR004 have now received the investigational therapy Rexlemestrocel-L, which is being evaluated for chronic back pain stemming from degenerative disc disease. The completion of the treatment phase marks a significant step forward for the programme.
Trial Design and Regulatory Backing
The study's primary endpoint measures pain intensity reduction over a 12-month period, with researchers seeking to demonstrate meaningful improvement both against baseline readings and relative to the control group. Safety outcomes are also being tracked throughout the follow-up window.
The US Food and Drug Administration has granted the trial Regenerative Medicine Advanced Therapy (RMAT) designation, a status reserved for therapies addressing serious conditions with unmet medical needs. Chronic back pain ranks among the leading drivers of long-term work disability globally, and current treatment options remain largely symptomatic rather than curative.
What Happens Next
With patient treatment now complete, the focus shifts to the observation and data analysis phase. Mesoblast expects to release top-line results — the core efficacy and safety findings from the study — in mid-2027. Those results will play a decisive role in regulatory submissions to health authorities across multiple jurisdictions.
Industry analysts have sized up the commercial opportunity for Rexlemestrocel-L as substantial should it reach the market. Peak sales estimates exceed US$10 billion, reflecting both the sheer prevalence of chronic back pain and the scarcity of regenerative alternatives for patients who have exhausted conventional care.
Financial Position and Market Response
Investors reacted favourably to the clinical progress. Mesoblast shares traded at A$2.34 following the announcement, up 6 percent. The company is dual-listed on the Australian Securities Exchange and the Nasdaq.
Alongside the trial update, Mesoblast disclosed fresh financial figures. Revenue for fiscal year 2026 reached US$115 million, generated by Ryoncil, the company's already-commercialised product. Cash on hand stood at US$103 million as of the reporting date, a cushion management says will fund ongoing operations and the completion of existing clinical programmes while preparations for a potential Rexlemestrocel-L launch move forward.
The mid-2027 data readout is now widely viewed as the next major inflection point, not just for the company's valuation but for the broader therapeutic landscape in spinal disorders. A successful outcome could give clinicians a biological option that either complements or replaces the symptom-management approaches that currently dominate care.
